NCT06716203
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
At risk: Primary completion moved at least 10 months later.
See at-risk trials from BrightGene Bio-Medical Technology Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Nov 14, 2026 Show 5 more changesShow less
- Start date: Dec 2, 2024 to Jan 3, 2025
- Enrollment closed, study ongoing
- Eligibility criteria expanded, about 13 words
- Secondary endpoints: details revised at 2 of 5 entries
- Site details revised
- Minor Start date changed from estimate of Dec 1, 2024 to Dec 2, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change From Baseline in Hemoglobin A1c (HbA1c)
Timeframe: Week 0 to Week 32
Secondary (5)
Change From Baseline in Body Weight
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of Participants With HbA1c Target Value of <7%
Percentage of Participants With HbA1c Target Value of <5.7%
Change From Baseline in Fasting Serum Glucose
Arms and interventions
Experimental: 5 mg BGM0504Experimental
Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Experimental: 10 mg BGM0504Experimental
Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
Placebo Comparator: PlaceboPlacebo comparator
Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Drugs: Drug: 5 mg BGM0504 Administered SC, Drug: : 10 mg BGM0504 Administered SC, Drug: Placebo Administered SC
Sites
1 site in 1 country
- Peking University People's HospitalBeijing, Beijing Municipality, China